SCHEMBL3594182

SCHEMBL3594182

CN(CCNC(=O)Cc1c[nH]c2ccccc12)C1CCCCC1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.61
ALDH1A1 P00352 3/20 0.61
LMNA P02545 2/20 0.61
MAPT P10636 1/20 0.61
MC4R P32245 1/20 0.53
MC5R P33032 1/20 0.53
MC3R P41968 1/20 0.53
BCHE P06276 2/20 0.52
ACHE P22303 2/20 0.52
MTNR1A P48039 2/20 0.51
MEN1 O00255 1/20 0.49
MAPK1 P28482 1/20 0.49
KMT2A Q03164 1/20 0.49
CCNE1 P24864 1/20 0.48
CDK2 P24941 1/20 0.48
CDK5 Q00535 1/20 0.48
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3602530 0.90 MAPT (0.58) SMN1; SMN2ALDH1A1LMNAMAPTBCHE
SCHEMBL5326162 0.87 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1LMNAMAPTMC4R
SCHEMBL5327203 0.86 BCHE (0.46) SMN1; SMN2ALDH1A1LMNAMAPTMC4R
SCHEMBL5326500 0.86 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1LMNAMAPTMC4R
SCHEMBL5393266 0.85 MAPT (0.45) SMN1; SMN2ALDH1A1LMNAMAPTBCHE
SCHEMBL5321149 0.85 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1LMNAMAPTMC4R
SCHEMBL5324226 0.85 BCHE (0.42) SMN1; SMN2ALDH1A1LMNAMAPTBCHE
SCHEMBL5323736 0.84 BACE1 (0.46) SMN1; SMN2ALDH1A1LMNAMAPTMC4R
SCHEMBL5404202 0.84 HTR2A (0.46) SMN1; SMN2ALDH1A1LMNAMAPTMC4R
SCHEMBL5320742 0.84 BCHE (0.42) SMN1; SMN2ALDH1A1LMNAMAPTBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 SMN1; SMN2 4228/4885ALDH1A1 662/4885LMNA 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.